Business
Medicenna Reports Third Quarter Fiscal 2025 Financial and Operational Results and Provides Anticipated Milestones
- Disease control rate (DCR) of 78% (7 of 9) in combination escalation arm of MDNA11 with Merck&#...
About this update from Medicenna Therapeutics Corp.
[{"type":"text","content":"Medicenna Reports Third Quarter Fiscal 2025 Financial and Operational Results and Provides Anticipated Milestones\n\n\n\n\n - Disease control rate (DCR) of 78% (7 of 9) in combination escalation arm of MDNA11 with Merck’s (known as MSD outside of Canada and the US) KEYTRUDA\n \n ®\n \n (pembrolizumab) in ongoing Phase 1/2 ABILITY-1 trial including one complete response, one partial response and five stable disease (as reported on Dec. 5, 2024)\n \n\n\n\n - MDNA11 continued to demonstrate deep and durable single agent activity, with a 30% (3 of 10) objective response rate (ORR) in the monotherapy dose expansion cohort in checkpoint-resistant patients (as reported on Dec. 5, 2024)\n \n\n\n\n - Anticipated H1/2025 milestones related to the ABILITY-1 trial includes completion of enrolment in MDNA11 monotherapy dose expansion arm and MDNA11 + KEYTRUDA\n \n ®\n \n combination dose escalation arm and initiation of combination dose expansion arm\n \n\n\n\n - MDNA113 advancing towards IND-enabling studies as a first-in-class, targeted and conditionally activated bispecific anti-PD1-IL2 immunotherapy\n \n\n\n\n - Ended quarter unchanged relative to previous quarter with $30 million in cash and equivalents (includes warrant exercises), expected to fund operations through mid-2026\n \n\n\n TORONTO and HOUSTON, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines, today announced its FY Q3 2025 financial results and provided its 2025 strategic outlook with anticipated milestones.\n \n\n “We are thrilled about the year ahead as we build on the significant progress we achieved last year,” said Dr. Fahar Merchant, President and CEO of Medicenna. “Our excitement is driven by the impressive response rates seen in the ABILITY-1 trial, particularly in the monotherapy arm where 5 patients responded to MDNA11 out of 20 patients with heavily pre-treated advanced solid tumors, including one complete response, despite all of them having failed prior checkpoint inhibitor therapies. Additionally, we are encouraged by early results from the combination dose-escalation arm, where two confirmed objective responses including a complete res...